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Abstract
The receptors tyrosine kinases (RTKs) for the colony stimulating factor-1, CSF-1R, and for
the stem cell factor, SCFR or KIT, are important mediators of signal transduction. The
abnormal function of these receptors, promoted by gain-of-function mutations, leads to their
constitutive activation, associated with cancer or other proliferative diseases. A secondary
effect of the mutations is the alteration of receptors’ sensitivity to tyrosine kinase inhibitors,
compromising effectiveness of these molecules in clinical treatment. In particular, the muta-
tion V560G in KIT increases its sensitivity to Imatinib, while the D816V in KIT, and D802V in
CSF-1R, triggers resistance to the drug. We analyzed the Imatinib binding affinity to the
native and mutated KIT (mutations V560G, S628N and D816V) and CSF-1R (mutation
D802V) by using molecular dynamics simulations and energy calculations of Imatinib•target
complexes. Further, we evaluated the sensitivity of the studied KIT receptors to Imatinib by
measuring the inhibition of KIT phosphorylation. Our study showed that (i) the binding free
energy of Imatinib to the targets is highly correlated with their experimentally measured sen-
sitivity; (ii) the electrostatic interactions are a decisive factor affecting the binding energy;
(iii) the most deleterious impact to the Imatinib sensitivity is promoted by D802V (CSF-1R)
and D816V (KIT) mutations; (iv) the role of the juxtamembrane region, JMR, in the imatinib
binding is accessory. These findings contribute to a better description of the mutation-
induced effects alternating the targets sensitivity to Imatinib.
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Introduction
Receptors tyrosine kinases (RTKs) act as primary mediators of the ligand-induced responses to
control cellular signaling. The type III RTKs, comprising the stem cell factor (SCF) receptor
KIT, the macrophage colony-stimulating factor-1 (CSF-1) receptor CSF-1R (or FMS), the
platelet-derived growth factor α and β (PDGFR-α and PDGFR-β) and the FMS-like tyrosine
kinase 3 (FLT3) receptors, are crucial for the development and physiology of different cells
under normal conditions, and are implicated in different diseases [1]. The ligand-induced
dimerization of the extracellular domain, leading to activation of the intracellular tyrosine
kinase domain (TKD), promotes a conformational switch of key regulatory elements—the acti-
vation (A-) loop, the Cα-helix and the juxtamembrane region (JMR)–from inactive to active
state (Fig 1A–1C) required for the phosphotransfer reaction [2]. Phosphorylation of specific
tyrosine residues in RTKs controls various inter- and intra-cellular signaling pathways. The
kinase activity and post-transduction processes are highly ordered and tightly regulated in nor-
mal cells [3]. Their constitutive activation promoted by mutations is associated with different
forms of cancer [3–6]. Conversely, constitutive loss of function CSF-1R mutations were
recently involved in severe neurodegenerative disorders [7]. RTKs are therefore crucial objects
for fundamental research in biology and important targets for drug development.
The high sequence similarity and structural conservation of the kinase ATP-binding pocket
—the site targeted by most kinase inhibitors—is the main challenge in the development of
selective inhibitors of tyrosine kinase activity. Nevertheless, many of such ATP competitive
inhibitors have been conceived and are currently used in the clinic or are under clinical trials.
Debates on development of either selective or multi-targets inhibitors are still ongoing. On the
one side, the use of a selective inhibitor of a particular kinase for a given tumor diminishes the
possible non-desirable side effects. On the other side, a multi-targeted inhibitor inhibits divers
signal transduction pathways that coexist in an apt tumor, thus providing a higher therapeutic
efficacy. The archetype of such multi-kinase inhibitors is Imatinib (marketed by Novartis as
Gleevec or Glivec), a rationally designed signal transduction inhibitor (antineoplastic agent),
that selectively binds to a limited number of targets (KIT, BCR/ABL, RET proto-oncogene,
CSF-1R, PDGFR-α and PDGFR-β) [8] and acts either as inhibitor (BCR/ABL, RET) or antago-
nist (KIT, CSF-1R, PDGFR-α and PDGFR-β) (DrugBank, http://www.drugbank.ca/).
Imatinib is successfully used for the treatment of several malignancies, such as Philadelphia
chromosome-positive chronic myelogenous leukaemia (CML) [9], acute lymphoblastic leukae-
mia (ALL) [10] and KIT-positive gastrointestinal stromal tumors (GISTs) [11]. However, after
several years of clinical use, it becomes clear that Imatinib-based treatment constantly results
in acquired resistance coming from appearances of point mutations in the target kinase. Those
mutations usually occur within amino-acid sequences that encode crucial structural (and func-
tional) elements of the kinase, such as the ‘gatekeeper’ residues [12–14], the P-loop [15–17],
the JMR and the A-loop amino acids [18,19]. In fact, therapeutic inactivation of protein creates
selective pressures for tumor cells, analogous to those in natural selection, to evolve towards
resistance phenomenon, mainly through the emergence of minor preexisting resistant clones
[20,21]. The molecular mechanisms of the target resistance to Imatinib are not yet fully under-
stood. The description of such mechanisms at the atomic scale will lead to the straightforward
development of new generation of tyrosine kinase inhibitors, effective against the mutated
targets.
Despite of numerous attempts, the structural-based explaining of Imatinib selectivity by the
targets is only partial [22–25]. Extensive computational studies shed light on different aspects
of Imatinib recognition by the native targets [26–31]. In particular, molecular dynamics (MD)
simulations and free energy calculations on kinase-Imatinib complexes indicated comparable
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Fig 1. Structure of cytoplasmic region in RTKs. (A-C)Crystallographic structures (referenced with pdb code) of KIT in the inactive
autoinhibited (1T45, left), inactive non-autoinhibited (1T46, middle) and active (1PKG, right) states are presented as cartoon. Zoomed views
(bottom panel) show the active site of receptor with DFGmotif (D810-F811-G812) represented in sticks. (D) Point mutations D816, V560 and
S628 are showed in KIT (inactive state) as balls. In (A-D) the key structural fragments are highlighted in color—the αC-helix is in green, the
activation loop (A-loop) is in red, the juxtamembrane region (JMR) is in orange. (E) Superposition of the Imatinib-binding site in structures of
KIT (green) and CSF-1R (blue) in their auto-inhibited state non-bound to imatinib (PDB codes: 1T45 and 2OGV, respectively) and the
structures of KIT (orange) and CSF-1R (yellow) bound to imatinib (1T46 and 4R7I, respectively). While a part of the JMR is absent in the
crystallographic data, the residueW550/557 is not shown in the structures bound to imatinib.
doi:10.1371/journal.pone.0160165.g001
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binding free energies of Imatinib to different kinases—Abl, KIT, Lck and Src [26]. Computing
the binding free energy of Imatinib to Abl with the hybrid method QM-MM/PBSA differenti-
ated the forces contributing to the inhibitor binding and showed that the van der Waals energy
was the main component favoring the binding of a non-protonated imatinib [32]. Another
detailed computational study applying FEP/MD simulations and umbrella sampling [33]
showed that the selectivity of Imatinib to Abl over Src is a consequence of distinct stabilities of
the targeted conformation of the kinase domain in the two receptors, which apparently affects
the conformational selection by the drug [27]. A similar conclusion was delivered for the Imati-
nib binding by the wild-type targets KIT and Lck [27].
The mutation effects on the energy of Imatinib binding to the kinases were computationally
studied for Bcr-Abl [29,34–36], FGFR [37,38] and KIT [39]. Exploring the X-ray structure of
Imatinib—KIT complex by diverse online servers lead to the prediction of the impact of KIT
mutations on the stability and dynamics of the non-bound target and to the evaluation of the
role of particular residues to Imatinib binding [39].
We have previously proposed mechanisms of the mutation-induced constitutive activation
of two RTKs, KIT and CSF-1R, having the equivalent D816V/D802V mutation [40,41]. These
two mutants are highly resistant to Imatinib [18,42]. We have shown that the structural and
dynamical effects induced by the KIT oncogenic mutations V506D/G, D816V/Y/N/H and
S628N (Fig 1D), correlate with the auto-activation rates of KIT mutants measured in vivo and
in vitro and their Imatinib sensitivity [43,44].
To examine rigorously the mutation-induced effects on Imatinib affinity towards these
RTKs, we studied the structural, dynamical and thermodynamic properties of molecular com-
plexes formed by their clinically relevant mutants and Imatinib. Two RTKs, KIT and CSF-1R,
each in the native and mutated states, with the point mutations either alternating sensitivity to
Imatinib or not, were considered as targets. As in our previous studies of non-bound KIT and
CSF-1R, we used all-atomMD simulations and binding free energy (MM/PBSA) calculation.
We aimed to distinguish between the binding affinities of Imatinib in the different complexes
and to identify the main factors driving the binding of Imatinib to the native and mutated tar-
gets. Our study demonstrated that the Imatinib binding energy to the native and mutated KIT
and CSF-1R targets is quite different. The electrostatic interactions between the protonated
Imatinib and the targets residues were identified as a main factor contributing to such differ-
ence, and their alternation leads either to Imatinib resistance or to increasing of the target sen-
sitivity to this inhibitor. Further, we experimentally evaluated the relative sensitivity of the
various KIT receptors to Imatinib by the inhibition of KIT phosphorylation. The two types of
data, obtained in silico and measured in vitro, were found to be highly correlated, strongly sug-
gesting that the chosen computational methods are satisfying to produce biologically interpret-
able results.
Materials and Methods
Targets selection
Structural models of the inactive state of the cytoplasmic domain of CSF-1R and KIT in their
native or wild-type (WT) (CSF-1RWT and KITWT) and mutated forms (CSF-1RD802V,
KITV560G, KITS628N and KITD816V) were selected from our previous MD simulations [40–44].
Representative conformations over the MD trajectories were extracted by a fast clustering,
based on convergence analysis [45]. Briefly, a first reference structure is initially picked up ran-
domly and associated with a bin of MD conformations distant by less than an arbitrary RMSD
cut-off (here we chose 2.0 Å); then other reference structures are picked up randomly among
the remaining MD conformations, in an iterative way until no MD conformations are
Mutation-Induced Resistance of Targets to Imatinib
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remaining. Then each MD conformation in the total pool is associated to its closest (RMSD)
reference structure, to form as many reference clusters. Considering only the Cα atoms, we
applied this technique to a concatenated trajectory of KIT, containing two MD replicas of 50
ns for each form of the protein (KITWT, KITV560G, KITS628N and KITD816V), and a
concatenated trajectory of CSF-1R, containing two replicas of 50 ns for each form of the pro-
tein (CSF-1RWT and CSF-1RD802V). Each MD replica contained 5 000 frames, but 500 frames
generated during the first 5 ns were discarded. The total number of conformations/frames are
36 000 for KIT and 18 000 for CSF-1R. Each concatenated trajectory was spliced into the ‘sec-
tions’ describing each form of the receptor. Generally, a good convergence is reached when
each reference structure is represented by conformations from all the parts of MD trajectories.
In our case, instead of taking this well-represented reference structures, we have chosen the
ones that were more represented for a particular target, instead of been visited by all forms,
WT or mutants, of CSF-1R and KIT. Only one structure for each form of KIT or CSF-1R was
selected for further calculations. Since the N-terminal portion of the JMR in these selected
structures is buried into the ATP-binding site provoking a clash with the inhibitor, the JMR
residues 543–581 in CSF-1R and 547–588 in KIT were manually removed from each selected
structure, except for KITV560G in which the JMR was truncated at position 558 to conserve the
mutated residue. Further, we have prepared the other KIT targets (KITWT, KITS628N and
KITD816V) with the JMR, truncated as in KITV560G.
Molecular docking
The preparation of the receptors and imatinib structures, as well as the docking runs, were per-
formed using the Schrödinger suite Maestro (Schrödinger Release 2014). The module protein
preparation wizard was used to re-assign hydrogens, charges and to minimize the structures of
WT CSF-1R/KIT and mutants, using the default parameters. Imatinib coordinates were
retrieved from the crystallographic structure of KIT in complex with this inhibitor– 1T46 [25].
Imatinib was prepared using LigPrep (Schrödinger Release 2014) in the environment at pH 7.0.
From the possible protonation states of Imatinib, generated by LigPrep, we have chosen the
protonated state (+1), which seems to be the correct state for this inhibitor in complex with
kinases, according to its predicted theoretical value [26]. The receptor structures were super-
posed to the crystal structure 1T46 to center the docking workspace on the ligand. The docking
calculations were performed by using the Induced Fit Docking (IFD) [46] with the Extended
Sampling protocol in which all targets residues positioned at a distance inferior to 5 Å from
Imatinib were considered flexible. The binding affinity of Imatinib to the targets was character-
ized by docking scores (GLIDE and IFD). Each docking model was superposed with the crystal
structure of the Imatinib-bound KIT (1T46) usingMaestro from the Schrödinger suite, and the
RMSD values were calculated in respect to 1T46. The best generated models of Imatinib•target
complexes (target is CSF-1RWT, CSF-1RD802V, KITWT, KITV560G, KITS628N and KITD816V with
the entirely truncated JMR), reconstituting the Imatinib position in 1T46, were used for MD
simulations. Imatinib was manually placed into KITWT, KITS628N and KITD816V structures
bearing the partially truncated JMR. This was easily done by superposition with the success-
fully docked complexes for their truncated forms. Possible steric clashes were eliminated by
energy minimization of the complexes.
Molecular dynamics simulations
Imatinib preparation. To generate the Imatinib topology parameters compatible with
CHARMM all-atoms force field [47], an Imatinib structure was retrieved from the Zinc Data-
base (http://zinc.docking.org/) and used as input for the web server Swissparam [48].
Mutation-Induced Resistance of Targets to Imatinib
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Set up of the systems. The set-up of MD simulations was performed with the
CHARMM27 all-atom force field integrated in GROMACS package 4.6.5 [49]. For simulations,
each model was placed in a cubic box and centred with a 1.2 nm distance to the faces under
periodic boundary conditions and solvated with explicit TIP3P water molecules [50]. Cl-
counter ions were added when necessary to neutralize the overall charge. The minimization
procedure consisted of two steps: (i) steepest descent energy minimization (EM) with the solute
atoms restrained and (ii) EM with all atoms free. The equilibration procedure was performed
on the solvent, keeping the solute atoms (except H-atoms) restrained for 500 ps at 310 K and a
constant volume (canonical NVT ensemble).
Production of MD trajectories. Two runs of 50-ns MD simulations were carried out for
each complex ‘Imatinib•target’ (target is CSF-1RWT, CSF-1RD802V, KITWT, KITV560G, KITS628N
and KITD816V with the entirely and partially cleaved JMR) and for each cleaved wild-type target
in absence of Imatinib, further called ‘non-bound’ or ‘apo’ form. The temperature of solute (Ima-
tinib•target) and solvent (water and ions) was separately coupled to the velocity rescale thermo-
stat [51] at 310 K with relaxation time of 0.1 ps. The pressure was maintained at 1 atm by
isotropic coordinate scaling (NPT ensemble) with relaxation time of 1 ps using Berendsen ther-
mostat [52]. A time step of 2 fs was used to integrate the equations of motion based on the Leap-
Frog algorithm [53]. The Lennard-Jones interactions were shifted to a cut-off 1.4 nm, and the
Particle Mesh Ewald (PME) method [54] was used to treat long-range electrostatic interactions.
The list for the electrostatic interactions was updated every 5 steps. All bonds were controlled
using the Linear Constraint Solver (P-LINCS) algorithm [55]. The SETTLE algorithm [56] was
used to constrain the water molecules geometry. Coordinates files were recorded every 10 ps.
Analysis of the trajectories. The MD trajectories were analysed (RMSDs and RMSFs
computation and Principle Component Analysis) with tools included in the GROMACS pack-
age. The first 5 ns of each trajectory (equilibration time), were removed prior to analysis. A
convergence analysis was performed using an ensemble-based approach described in details in
[40–41,44]. Each analysis was performed on 9 000 conformations generated over two MD runs
of 45 ns per simulation. Visual inspection of the MD data was made with PyMOL [57] and
VMD [58]. Graphs were generated using Grace (http://plasma-gate.weizmann.ac.il/Grace/).
Free energy calculation
Standard MM-PBSA (Molecular Mechanics—Poisson Boltzmann Surface Area) method [59]
has been used for calculation of thermodynamic parameters and free energy of binding. In
MM-PBSA, the free energy difference of binding (ΔGbind) between a ligand (L is Imatinib) and
a receptors (R) to form a complex RL is defined as:
DGbind ¼ DH  TDS ffi DEMM þ DGsol  TDS ð1Þ
DEMM ¼ DEint þ DEelect þ DEvdw ð2Þ
where ΔEMM, ΔGsol and −TΔS are the changes of the gas phase MM energy, the solvation free
energy and the conformational entropy upon binding, respectively.
ΔEMM includes ΔEint (covalent bonding including the bond, angle and dihedral energies),
electrostatic ΔEelect and van der Waals ΔEvdw energies. ΔGsol is the sum of the electrostatic sol-
vation energy (polar contribution) and non-electrostatic solvation component (non-polar con-
tribution). The polar contribution was calculated using PB model, while the non-polar free
energy estimated by solvent accessible surface area (SASA).
ΔGbind was computed for each generated Imatinib•target complex over the merged trajecto-
ries containing 9 000 frames (and also for the individual MD simulation replicas over a
Mutation-Induced Resistance of Targets to Imatinib
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trajectory containing 4500 frames). We used the g_mmpbsamodule of GROMACS, which
combines subroutines from GROMACS and APBS [60] to calculate the enthalpy contribution
(ΔH) to the Gibbs free energy and the per-residue energy decomposition. The energy compo-
nents ΔEMM and the polar and non-polar components of ΔGsol were calculated in the bound
and unbound form, and subsequently their contribution to the binding energy DRBEx of residue
x [61] was calculated as follows:
DRBEx ¼
Xn
i¼0ðA
bound
i  Afreei Þ ð3Þ
Where Aboundi and A
free
i are the energy of ith atom from x residue in bound and free forms,
respectively, and n is the total number of atoms in the residue.
The g_mmpbsamodule does not include the calculation of entropic terms and therefore it
gives the relative binding energy. Since we have used the same compound (Imatinib) interact-
ing with proteins of similar structures and showing the same binding mode, the entropy contri-
bution was neglected [62].
Data simulation analysis
Electrostatic potential surface. The electrostatic potential surface was computed with the
APBS software running through the PDB2PQR webserver (http://nbcr-222.ucsd.edu/pdb2pqr/).
As the input data, the equilibrated conformations of the Imatinib-target complexes prior to MD
simulations, were used.
Salt bridges. The salt bridges occurrences were calculated for the merged trajectories con-
taining 9 000 frames using the Timeline plugin available with VMD. The residues-pair selection
was made within a cutoff distance of 10 Å from Imatinib. Plots were generated using R software
[63], discarding interactions occurring less than 10% of the simulation time.
Inhibition of KIT phosphorylation
Cell transfection. COS-7 cells were transfected with 1 μg of KITWT, KITD816V, KITV560G
or KITS628N expression vectors with FuGENE 6 (Promega). Twenty four hours following trans-
fection, cells were split in four 60-mm plates and serum-starved overnight in Dulbecco’s modi-
fied Eagle’s medium with 0.5% FBS. Cells were then treated for 90 minutes with Imatinib at
concentrations ranging from concentration 0 to 5μM. Cells transfected with hKIT WT were
stimulated for 5 min with 250 ng/ml murine SCF at 37°C.
Immunoblotting. Cells were washed in ice-cold phosphate-buffered saline (PBS), pelleted,
and lysed in HNTG buffer (50mMHEPES [pH 7], 50mM NaF, 1mM EGTA, 150mM NaCl,
1% Triton X-100, 10% glycerol, 1.5 mMMgCl2) containing the protease inhibitor mix Com-
plete EDTA-free (Roche Applied Science) and 100 μMNa3VO4. Proteins were separated on
SDS-polyacrylamide gels and transferred to Immobilon-P membrane (Millipore). Membranes
were saturated with 5% bovine serum albumin (Euromedex) and probed with phospho-c-Kit
(Tyr719) (Cell Signaling Technology) and c-Kit (D13A2) antibodies (Cell Signaling Technol-
ogy). Signals were revealed using horseradish peroxidase-conjugated secondary antibodies and
SuperSignal West Pico Chemiluminescent Substrate (ThermoScientific).
Results and Discussions
Imatinib docking into the targets
For the study of stability of the Imatinib•target complexes and the comparison of their free
binding energy, we used the representative conformations of the inactive form of native (or
wild-type, WT) and mutated kinase domain of two proteins, CSF-1R (CSF-1RWT and
Mutation-Induced Resistance of Targets to Imatinib
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CSF-1RD802V) and KIT (KITWT, KITD816V, KITV560G and KITS628N), selected from our previ-
ous MD simulations [40–41, 43–44]. Our earlier attempts to dock Imatinib into the inactive
form of the kinase domain of KIT and CSF-1R have failed [64], probably due to the buried con-
figuration of the JMR. To clarify the reason of this failed assay, we compared the crystallo-
graphic structures of KIT and CSF-1R bound and non-bound to Imatinib– 1T46 [25], 4R7I
[65], 2OGV [66] and 1T45 [25], respectively. We observed that the JMR buried configuration
and the side-chain orientation of residues W550/557 and F798/811 (CSF-1R/KIT) in both
receptors, impairs the binding of Imatinib into the ATP-binding site (Fig 1E). Repositioning of
the side chain of F811/797 in KIT/CSF-1R bound to Imatinib, evidenced by crystallography
(1T46/4R71), confirms its inhibitor-induced (or inhibitor-selected) relocation. The Imatinib
binding effect on the JMR residue W550/557 (CSF-1R/KIT) inserted in the binding pocket
remains obscure, because the N-extremity of the JMR is not resolved in the crystallographic
structures 1T46 and 4R7I, suggesting that this portion might be very flexible and dislocated
from the kinase domain. To avoid steric hindrance, we removed the JMR from the selected
MD conformations, producing suitable targets for the docking procedure. In the mutant
KITV560G, to conserve the point mutation, the JMR was truncated at position 558, yielding a
target, longer by 30 residues (V558-R588) than the other targets. Expecting a tiny impact of
this JMR partial fragment on Imatinib binding, we have accepted such exception to compare
the Imatinib binding to all studied targets.
The optimised structure of the protonated Imatinib [26], generated with Ligprep, was suc-
cessfully docked into each prepared target (see Methods). The best docking poses of Imatinib
show a striking similarity in all studied proteins (Fig 2D, insert) and all are very close to that
observed in the crystallographic structure of Imatinib•KIT (1T46) and Imatinib•CSF-1R (4R7I)
complexes, in which the position of Imatinib and its conformation is virtually identical (Fig A in
S1 File). Taking 1T46 as a reference, the docking poses, showing Root Mean Square Deviation
(RMSD) values less than 1 Å and reproducing five H-bonds described in the crystallographic
structure, were preselected. The best poses, ranked by RMSDs and GLIDE scores, were retained
for further analysis. The GLIDE scores of the best poses, ranging from -9.2 to -6.3 kcal/mol over
the generated complexes, showed a common tendency to be diminished (higher affinity) in the
native proteins and KITV560G, and worse in the resistant mutants (Table 1). Although GLIDE
docking scores show only qualitative correlation with the experimentally determined Imatinib
affinity, their values help the choice of ‘Imatinib•target’ complexes further studied by MD simu-
lations. The IFD scores, distributed in a narrower range, from -12.78 to -10.96 kcal/mol, do not
significantly distinguish the binding affinity of Imatinib to the different targets.
Molecular dynamic simulations of CSF-1R and KIT complexes
To get further insight into the molecular mechanisms of the resistance to Imatinib, it is of pri-
mary importance first to investigate the structural and dynamical properties of the Imatinib-
bound targets and second, to define the energy-related parameters driving the molecular com-
plex formation and stability. For these purposes, we performed MD simulations on Imatinib-
bound receptors, KIT and CSF-1R, in the native and mutated forms.
Stability of the target•Imatinib complexes. The RMSDs calculated on the backbone
atoms from the initial structures of CSF-1R and KIT in their free and bound states are relatively
stable over MD simulations, except the very flexible residues located at the C-terminal loop of
both receptors, which are significantly contributing to the RMSD values increase. These resi-
dues (7/6 residues from the C-terminal of CSF-1R/KIT) were excluded from the RMSD analy-
sis. Overall, the RMSD values in almost all simulated complexes vary around 0.15–0.20 nm
(Fig 2 and Fig B in S1 File), while one of the two MD simulations replica of each receptor
Mutation-Induced Resistance of Targets to Imatinib
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possessing the equivalent mutation, D802V (CSF-1R) or D816V (KIT), shows slightly
increased RMSD values (0.25 and 0.35nm, respectively).
To identify the residues responsible for this increased structural instability, we computed
the Root Mean Square Fluctuations (RMSFs) of all amino acids in each protein. The MD
Fig 2. MD simulations of the RTK-Imatinib complexes. (A-B) The Root Mean Square Deviation (RMSD) values of the native non-
bonded receptors (CSF-1RWT-APO and KITWT-APO) and the complexes formed by Imatinib and the native receptors (CSF-1RWT and KITWT)
and their mutants (CSF-1RD802V, KITD816V, KITV560G and KITS628N) were calculated for the backbone atoms from trajectories 1 and 2
(orange and blue respectively) of MD simulations of all studied systems. (C) Simulated complexes were obtained by the docking of Imatinib
(in green) to the active site of each receptor. The JMR was removed prior the docking procedure. The superimposed receptors CSF-1R/KIT
are shown as grey/cyan cartoons. The key structural fragments of receptors, the αC-helix and the activation loop (A-loop) are highlighted in
cyan/brown (CSF-1R/KIT) and in red/rose (CSF-1R/KIT) color respectively. Insert in C: The best docking poses of Imatinib bound to CSF-
1RWT(blue), CSF-1RD802V(orange), KITWT(cyan), KITV560G(green), KITS628N(pink) and KITD816V(magenta) superposed with the
crystallographic structure 1T46 (grey). The protein backbone and Imatinib are represented in cartoon and sticks, respectively.
doi:10.1371/journal.pone.0160165.g002
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RMSFs, usually coupled with the 3D interpretation of the temperature factors (beta-values)
from crystallographic data, show that the highest atomic fluctuations are principally observed,
as was expected, in some particular loop regions, as we established previously in the non-
bonded targets [41,43,44]. Comparing the native non-bound targets, CSF-1R and KIT, we note
some differences in the atomic fluctuations of residues from the molecular fragments involved
in the activation process—the catalytic (C-) loop, the activation (A-) loop and the loop preced-
ing αC-helix, annotated on Fig 3 as 6, 7 and 3, respectively. When analysing the Imatinib-
bound complexes, we remarked that binding of Imatinib influences differently the atomic fluc-
tuations of the native and mutated targets.
In both Imatinib•CSF-1R complexes, formed by the native and mutated receptors, we
observed an alteration of atomic fluctuations respectively to those in the non-bound target—
higher for residues of the loop preceding the αC-helix (3 in Fig 3), and diminished for residues
of the 310-helix of A-loop (7 in Fig 3). The RMSFs of the N-lobe loops residues (2 and 4 in Fig
3), showing similar values in the non-bound target (CSF-1RWT/APO) and in Imatinib•CSF-
1RWT complex, are significantly diminished in the complex formed by the mutated target CSF-
1RD802V. The P-loop residues (annotated as 1 in Fig 3) show diminished RMSFs in complexes
compared to non-bound receptor.
In KIT complexes, the RMSFs pattern generally corresponds to that in CSF-1R’s (Fig 3).
Nevertheless, some features, characterizing the atomic fluctuations in KIT, mutated or not,
bound or not to Imatinib, were different from those in CSF-1R’s. In particular, in the non-
bound native KIT, the RMSFs of residues from the loop (3) preceding the C-helix are increased
respective to those in CSF-1R, whereas they are significantly diminished in the A-loop 310-
helix (7) and in the catalytic (C-) loop (6). When KIT is bonded to Imatinib, the RMSF values
in the N-lobe’s loop preceding the C-helix are diminished in the native target—the effect oppo-
site to those observed in CSF-1R–, while in complexes formed by the mutants theirs values are
conserved. For the Imatinib-bound KITV560G and KITS628N mutants, specifically, the increasing
of RMSFs is observed for residues from the A-loop (annotated as 7’ in Fig 3) and the C-lobe
loop preceding G-helix (9 in Fig 3). One of the differences between the two receptors, KIT and
CSF-1R, is the atomic fluctuations of the catalytic (C-) loop residues. These values are dimin-
ished in both CSF-1R complexes compared to the non-bound target—significantly in Imati-
nib•CSF-1RWT and moderately in Imatinib•CSF-1RD802V. Apparently, the increase of the C-
loop atomic fluctuations in Imatinib•CSF-1RD802V complex is directly related with the alter-
ation in the H-bonds pattern involving residues of the C- and A-loops (Table 2). In all KIT tar-
gets, wild-type and mutated, bound or not, the RMSFs of the catalytic (C-) loop are similarly
very small.
The H-bonds pattern stabilizing the Imatinib binding in the complexes. The five H-
bonds observed in the crystallographic structures (1T46 and 4R7I for KIT and CSF-1R,
Table 1. Imatinib docking into the native targets (CSF-1RWT and KITWT) and their mutants (CSF-1RD802V, KITV560G, KITS628N and KITD816V). The two
energy values, the GLIDE and Induced Fit Docking (IFD) scores, were produced with MAESTRO (Schrödinger release, 2014). The RMSD values were calcu-
lated for the predicted docking poses taking crystallographic structure 1T46 as a reference. The IC50 values (μM) are taken from the literature.
Target/Parameter Score Glide (kcal/mol) Score IFD (kcal/mol) RMSD (Å) IC50
Reference (μM)
CSF-1RWT -7.9 -10.9 0.5 0.3 [42]
CSF-1RD802V -6.3 -12.4 0.5 >4 [42]
KITWT -7.8 -12.2 0.5 0.1–1 [18,19]
KITV560G -9.2 -12.1 0.6 0.025 [18]
KITS628N -8.6 -12.3 1.0 not determined
KITD816V -7.0 -12.1 0.4 >10 [19]
doi:10.1371/journal.pone.0160165.t001
Mutation-Induced Resistance of Targets to Imatinib
PLOS ONE | DOI:10.1371/journal.pone.0160165 July 28, 2016 10 / 25
respectively) and described as the principal non-covalent contacts stabilising the binding of
Imatinib to the native targets (KITWT and CSF-1RWT), are well preserved along MD trajecto-
ries (Fig 4A and 4C, scheme on the left). These H-bonds are formed by functionally significant
amino acids in KITWT/CSF-1RWT–the gatekeeper residue T670/663, the highly conserved
Fig 3. MD simulations of the RTK-Imatinib complexes. (A) The Root Mean Square Fluctuations (RMSFs)
computed on the backbone atoms averaged over the total production simulation time of CSF-1RWT and CSF-
1RD802V (blue and red, respectively) (top panel) and of KITWT, KITD816V, KITV560G and KITS628N (blue, red,
yellow and green, respectively) complexes (bottom panel) were compared to those in the non-bound
receptors (dotted black lines). (B) The average conformations of CSF-1R (top panel) and KIT (bottom panel)
are presented as tubes. The tube size is proportional to the residue atomic fluctuations computed on the
backbone atoms. The highly fluctuating regions are colored in red and numerated for CSF-1R in (A) and (B).
doi:10.1371/journal.pone.0160165.g003
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residue E640/633, the DFG residue D810/796, the hinge residue C673/666 and the C-loop resi-
due I789/775. Over MD simulations of Imatinib•KITWT/CSF-1RWT complexes, these H-bonds
are characterized by high, moderate or low occurrence values– 98% (C673/666), 47/38%
(T670/663), 42/37% (D810/796), 12/34% (E640/633) and 96/98% (I789/775), respectively
(Table 3, Scheme A in S1 File).
This analysis shows that in KIT and CSF-1R complexes formed by the native targets, the H-
bonds of Imatinib with the hinge residue C673/666 and with the hydrophobic residue I789/775
are constantly and similarly maintained during the MD simulations with an occurrence close
to 100%. The other H-bonds, characterised by relatively lower occurrences, show some differ-
ence between the two targets. In particular, the H-bond of Imatinib with D810 in KIT shows
higher occurrence (42%) than compared to E640 (12%), while the corresponding H-bonds in
CSF-1R have similar occurrence. The H-bonds involving the residue T670/663 have close
occurrences in both native targets.
As it was evidenced by the analysis of different X-ray structures, all these H-bonds stabiliz-
ing Imatinib in the binding site are observed in complexes formed by KIT, CSF-1R and other
tyrosine kinases, while the author’s interpretation of the observed contacts may differ. For
instance, in the crystal structure of KIT complexed with Imatinib (1T46) [25], the Imatinib
interactions with I789 through the N-methylpiperazine fragment was described as non-spe-
cific. In the recently solved structure of Imatinib in complex with CSF-1R (4R7I) [3], this con-
tact is considered as alternative to that with H776. In other structures of kinases complexed
with Imatinib, such as Abl (2HYY) [67], c-Src (2OIQ) [22] and DDR1 (4BKJ) [68], the N-
methylpiperazine fragment of Imatinib makes direct contacts with a hydrophobic residue (iso-
leucine or valine) and with histidine. Such interpretation of the N-methylpiperazine moiety’s
stabilising contacts is probably related to considering the Imatinib as a neutral molecule over
the structure refinement in the X-ray analysis. Therefore, our interpretation of Imatinib contact
with I789 as a strong and stable H-bond interaction should be considered for the improving or
the development of kinase inhibitors.
In CSF-1RWT and CSF-1R mutant, the H-bond interactions stabilizing Imatinib in its bind-
ing site are overall conserved; however, their occurrence values vary significantly among the
different mutants (Table 3). In particular, an essential decrease of the H-bond occurrence is
detected for the interaction of Imatinib with I775 in CSF-1RD802V (18% against 96% for CSF-
1RWT. In KIT D816V the occurrences for the same H-bonds were surprisingly maintained. I775/
789 (CSF-1R/KIT) is placed in the C-loop, and the binding of this residue with Imatinib corre-
lates directly with the C-loop RMSFs observed in the related proteins.
Table 2. H-bonds between the A- and C-loops residues in CSF-1R and KIT. Occurrences (in %) of the H-bonds are averaged over the two MD replicas.
Contact/Target CSF-1RWT Im•CSF-1RWT Im•CSF-1RD802V
D778  N783 92 100 70
D778  H776 69 60 67
D778  R801 93 78 1
D778. . .Y809 18 39 78
D778  R782 2 7 94
Contact/Target KITWT Im•KITWT Im•KITD816V
D792  N797 50 51 89
D792  H790 23 34 43
D792  R815 100 100 74
D792  Y823 47 45 45
doi:10.1371/journal.pone.0160165.t002
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Fig 4. Imatinib binding to CSF-1R and KIT. (A) 3D structure of Imatinib•target complex illustrated by using KITWT bound with Imatinib.
Imatinib and interacting residues of receptor are showed by sticks. (B) Graphical representation of the free binding energy (ΔG) of
Imatinib•target complexes. The computed total ΔG energy value (this work) and the experimentally measured affinity (the literature data and
the present data) are shown for each complex. (C) The H-bonds (dashed lines) pattern stabilizing Imatinib in complexes formed by the
native KIT and its mutants KITD816V and KITV560G (left), and in mutant KITS628N (right).
doi:10.1371/journal.pone.0160165.g004
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As expected, given its higher sensitivity to Imatinib compared to KITWT, KITV560G binds
Imatinib through H-bonds characterised by higher occurrences than in KITWT, particularly for
interactions with D810 (73% vs 42%) and D640 (46% vs 12%). Some change in occurrences of
the H-bond interactions was also evidenced in the Imatinib•KITS628N complex, formed by a
mutant recently found in a metastatic melanoma and described as still sensitive to Imatinib
[43]. In this complex, mutation affects mainly the inhibitor interactions with residues I789 and
D810, which are reduced for I789 (33% vs 98%) and increased for D810 (68% vs 42%). Further-
more, Imatinib interacts with residue D810 by H-bond with the δ-oxygen atom in KITS628N, a
contact that was not observed in complexes formed by the other targets (Table 3, Scheme A in
S1 File). Visual inspection of the Imatinib•KITS628N MD conformations showed that this H-
bond occurs due to a flip of the N-methylpiperazin fragment of Imatinib and a change on the
side chain orientation of D810, favouring the interaction between the inhibitor and the D810
δ-oxygen atom (Fig 4, scheme on the right). Such conformational adaptation of both interact-
ing partners, target and inhibitor, induces a significant diminishing or entire loss of the inhibi-
tor interaction with I789 (33% KITS628N vs 98% in KITWT) but stabilizes the bifurcate H-bond
with D810 side chain. For each complex, the H-bonds patterns stabilizing the Imatinib-target
binding and the H-bonds occurrences were similar when either the individual or concatenated
MD trajectories were analyzed (Table 3, Table A in S1 File).
The free binding energy in Imatinib•target complexes and its relation with
targets sensitivity to Imatinib
The conformational change in the ATP-binding site is a footprint of the induced-fit mecha-
nism according of which the protein adapts its active site conformation to accommodate the
ATP or inhibitor. Previously, based on normal modes analysis, it was concluded that KIT
mutants (including D816V) had a decrease in flexibility of the majority of residues that partici-
pated in the binding of Imatinib [39]. In our MD simulations, the H-bond pattern found for
KITD816V indicates an increased rigidity of the ATP-binding site. Due to the reduced flexibility,
residues forming the ATP-binding site in KITD816V, would be less able to adapt their confor-
mation over the recognition process, possibly reducing the affinity for the inhibitor. In con-
trast, the conformational adaptation of mutated target (in Imatinib•KITV560G) or together with
the inhibitor (in Imatinib•KITS628N) may be sufficient to reach a good affinity between two
partners.
Experimental evaluation of KIT sensitivity to Imatinib. To clarify the role of the S628N
substitution in KIT, we determined experimentally the relative sensitivity of the various KIT
(KITWT, KITD816V KITV560G and KITS628N) receptors. COS7 cells were transfected with the
corresponding expression vectors, and were then treated with various concentrations of
Table 3. Imatinib binding to the targets. Occurrences of the H-bonds between Imatinib and the targets residues were averaged over each of the two MD
replicas. Imatinib atoms participating in the interactions with the targets are represented in Scheme A in S1 File. The atom pairs for donor-acceptor interac-
tions are depicted in the Table.
Target/Atoms N3-(N)C666 O1-(N)D796 N7-(Oδ)D796 N7-(O)I775 N5-(Oε)E633 N4-(Oγ)T663
CSF-1RWT 98 37 0 96 34 38
CSF-1RD802V 99 26 0 18 34 51
N3-(N)C673 O1-(N)D810 N7-(Oδ)D810 N7-(O)I789 N5-(Oε)E640 N4-(Oγ)T670
KITWT 98 42 0 98 12 47
KITV560G 98 73 0 95 46 34
KITS628N 93 68 56 33 34 27
KITD816V 98 60 0 99 27 51
doi:10.1371/journal.pone.0160165.t003
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Imatinib ranging from 0.01 to 5 μM. The inhibition of KIT phosphorylation was then evaluated
by western-blotting (Fig 5). As previously described, KITD816V was not affected even at 5 μM,
while KITWT was partially inhibited at 0.1 and fully inhibited at 1 μM. As expected also,
KITV560G was inhibited at 0.1μM. Finally, KITS628N had an inhibition comparable to KITWT.
Consequently, the experimental data indicates the following order of KIT sensitivity to Imati-
nib: KITV560G> KITWT = KITS628N>> KITD816V.
The binding free energy of Imatinib•target complexes. Since the H-bonds pattern does
not explain exhaustively a difference of the Imatinib binding to the sensitive and resistant tar-
gets, we further analysed the binding free energy, (ΔΔG), [69] of Imatinib to each target using
the MM/PBSA approach [59]. The binding free energy values are considerably different in the
studied complexes (Fig 4B). The lowest (-94 kcal/mol) and the biggest (-42/-43 kcal/mol) values
are found in complexes formed by the most sensitive (KITV560G) and the most resistant (CSF-
1RD802V and KITD816V) targets to Imatinib, respectively. Based on these binding free energy val-
ues, the in silico estimated sensitivity of the studied targets to Imatinib may be described by the
following order—KITV560G> CSF-1RWT/KITWT KITS628N CSF-1RD802V/KITD816V and
CSF-1RWT/KITWT> CSF-1RD802V/KITD816V, which is qualitatively very consistent with our in
vitro data.
In general, the experimentally measured sensitivity of the different KIT receptors to Imati-
nib shows the same tendency as predicted by the free energy of binding calculations. Only the
KITS628N energy profile could not be significantly distinguished in silico from those of KITWT
and KITD816V. Such divergence between the theoretical prediction and the experimentally mea-
sured values may be attributed to the limitation of the MM/PBSA method, in comparison to
more accurate approaches such as alchemical free energy perturbation molecular dynamics
(FEP/MD) [70].
However, high absolute quantitative accuracy was not in the scope of the present study that
focuses on the discrimination of Imatinib binding by the native and mutated targets (RTKs).
To our knowledge, this demonstration of a difference in the energy of binding of Imatinib to
the native and resistant forms of these two kinase targets, evidenced computationally, is new.
The binding energy alteration in Imatinib-targets complexes together with the earlier described
mutation-induced perturbation of the Imatinib-specific inactive conformation as an important
step for transition toward the constitutively active form [41,44], fully explain the resistant pro-
file of the studied CSF-1RD802V/KITD816V mutants.
Fig 5. Inhibition of KIT phosphorylation by Imatinib.Cells expressing KITWT, KITD816V, KITV560G or
KITS628N were treated with the indicated concentrations of Imatinib for 90 minutes. Protein lysates were
analyzed by western-blotting to reveal KIT protein expression (KIT) and KIT phosphorylation (Phospho-KIT)
as readout of Imatinib inhibition. Two independent experiments were performed.
doi:10.1371/journal.pone.0160165.g005
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Since Imatinib is held in the kinase pocket via an extended network of hydrogen bonding
and charge-charge interactions, the decomposition of the binding free energy on the different
terms contributing to the binding affinity of Imatinib helps to identify the primary forces driv-
ing such binding and to analyze their variations among different complexes. The electrostatic
energy (ΔGelect) shows more variation (from -106 kcal/mol in KIT
V560G to -54 kcal/mol in
CSF-1RD802V) than the others terms and appears to be the principal force contributing to the
difference in the final binding energy values (ΔGbind) in the studied complexes (Table 4,
Table B in S1 File). The correlation coefficient between ΔGelect and ΔGbind is 0.89. The solvation
energy (ΔGsol) and the van der Waals dispersion energy (ΔGvdw) show only minor variations
among the studied complexes (ΔΔGsol and ΔΔGvdw is less than 10 and 3 kcal/mol, respectively).
The significant role of the electrostatic component in the Imatinib binding affinity to KIT was
reported earlier [27]. Recently, the analysis of the reported literature binding energies of Imati-
nib to tyrosine kinases, obtained by molecular mechanics (MM) and those found by quantum
mechanics (QM), suggested that solvation energies are a major component of the overall bind-
ing energy [71].
In our quite simply analysis, we have shown that KIT V560G has the most favorable protein-
Imatinib electrostatic interactions, greater than the native targets, KIT and CSF-1R, suggesting
that mutation V560G promotes the largest electrostatic stabilization of the Imatinib binding.
On the contrary, mutation D802V in CSF-1R and D816V in KIT, diminishes the electrostatic
interactions with Imatinib.
The per residue energy contributions to the binding energy. To identify the key molecu-
lar determinants responsible for Imatinib binding to the targets, we calculated per residue
energy contribution of all protein residues to the overall binding energy. As was expected, the
free energy binding value is mostly influenced by the charged residues,–either favorably
(impact of the negatively charged amino acids, asparagine and glutamic acid)–or unfavorably
(impact of the positively charged residues, arginine and lysine) demonstrating nearly similar
contributions from the corresponding residues in CSF-1R and KIT (Tables C and D in S1 File).
The substitution of an aspartate for a valine (D!V) in CSF-1RD802V and KITD816V reduces sig-
nificantly the residue energy contribution—from -8 kcal/mol (CSF-1RWT/KITWT) to 0 kcal/
mol (CSF-1RD802V/KITD816V). In KITV560G, the residue V560G, distant by ~8 Å from the Ima-
tinib, does not contribute considerably (-0.3 kcal/mol) to the binding energy. Similarly, in
KITS628N, the native or mutated residue affects lowly the binding energy. This estimation also
evidenced that the equivalent Imatinib-binding site residues (in CSF-1R and KIT), making
direct contact with the inhibitor, contribute almost similarly to the binding energy and show
only small differences between the native and mutated targets.
The JMR role in the Imatinib binding. Since the ΔGbind energy associated with the bind-
ing of Imatinib to KITV560G is low compared to the native protein and to the other studied tar-
gets, we evaluated the role of the partial JMR fragment, considered for the calculations in this
Table 4. The free energy of binding in the Imatinib-targets complexes. The free binding energy (ΔGbind) and contributions of electrostatic (ΔGelect), van
der Waals (ΔGvdw) and solvation (ΔG solv) energies were calculated using MM-PBSA. All energies are in kcal/mol.
RTK ΔGvdw ΔGelect ΔGsol ΔGbind
CSF-1RWT -66 -76 73 -69
CSF-1RD802V -66 -54 78 -42
KITWT -67 -75 81 -61
KITD816V -66 -56 80 -43
KITV560G -64 -106 76 -94
KITS628N -67 -67 83 -51
doi:10.1371/journal.pone.0160165.t004
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mutant. The newly generated MD trajectories of the Imatinib•KIT complexes (where
KIT = KITWT, KITS628N and KITD816V, having the same portion of the JMR (partially cleaved)
as the mutant KITV560G), were used for the ΔGbind energy calculation.
Comparing the data (MM-PBSA) obtained for Imatinib•KIT complexes formed by (I) the
targets having the partial JMR (Fig C in S1 File) and (II) the targets with the entirely cleaved
JMR (Fig 4B), we observed that (i) the tendency of the computed free energy of binding in the
two types studied complexes, formed by either the targets with totally cleaved JMR or having
partially cleaved JMR, is maintained; (ii) the free binding energy values are systematically
lower in all complexes of type (I) in respect to those of type (II); (iii) the difference in free
energy binding between the imatinib-bound complexes formed by KITD816V and KITWT con-
sists of 20–30% in the two types of complexes (I) and (II); (iv) the values of ΔGbind in com-
plexes formed by KITS628N and KITWT targets, having the partial JMR, are close. All these
observations indicate that the length of receptor, of type (I) or (II), influences the free energy
values but has only a tiny impact on the qualitative results distinguishing the energy binding to
the different targets. The last observation, (iv), corresponds well to the experimentally mea-
sured data that indicate the similar sensitivity of these proteins to Imatinib.
Contributions of residues positioned out of the ATP-binding site to the binding
energy. Considering the inhibitor-target recognition as a cooperative process, we showed that
the protein residues positioned at the vicinity of the ATP-binding site might affect the global
binding energy. We have subtracted the energy contributions of the residues from mutant with
those of the native protein, and the obtained increments (ΔΔG), ‘positive’ or ‘negative’, are
illustrated in Fig 6.
In CSF-1R, except the most important impact of D802, several residues participate to either
increase the unfavorable contribution (K616) or reduce the favorable contribution (E626, I775
and D837) to the binding energy. With exception of I775, all these residues are not bound
directly to Imatinib (Fig 4). As a ‘positive’ effect on the Imatinib-CSF-1R recognition, we noted
only a diminishing of the unfavorable contribution (R777) and a small increasing of the favor-
able contribution (E628) in the mutant respectively to the native protein. The difference in the
residual contributions (ΔΔG) in KITD816V, in general, is close to those in CSF-1RD802V. In par-
ticular, the residues contributing negatively to the Imatinib binding, besides of the important
impact of the D816V substitution, are D810, making H-bond with Imatinib, and K623, not
interacting directly with Imatinib.
Such repartition of the favorable and non-favorable contributions resulted in a global
diminishing of Imatinib affinity to CSF-1RD802V and KITD816V mutants, explaining its resis-
tance to the drug. Curiously, all H-bonds stabilizing Imatinib binding by KIT are preserved in
KITD816V mutant. Moreover, D810 forms more prevalent H-bonds (60%) in Imatinib•
KITD816V complex compared to Imatinib• KITWT. It is not excluded that in KIT, together with
electrostatic interactions, the dispersion contribution is also important in the Imatinib binding.
According to the literature, in KITWT, the disperse interaction energy was estimated to be -7.1
kcal/mol, while the electrostatic contribution is 4.7 kcal/mol [27]. Moreover, the water mole-
cules localized in the binding pockets may contribute significantly to the Imatinib affinity, as
was reported in this study. Despite the H-bond pattern conservation, the overall energy in the
Imatinib complex formed by the KIT mutant is considerably changed as we demonstrated
using MM/PBSA method. A more detailed computation based on alchemical FEP/MD simula-
tions could be useful to investigate further the molecular determinants of the KITD816V
resistance.
Comparing KITWT and KITV560G, we noted that the ‘positive’ increment in the binding
energy of the mutant is furnished by residues E633, E640, D792, and R815 that contribute sig-
nificantly to the Imatinib affinity either by impact of the negatively charged residues E633,
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E640 and D792 or by diminishing of the unfavorable interaction by R815. Such increase of the
favorable interactions could be a main factor contributing to the higher affinity of Imatinib to
KITV560G compare to the native target (Fig 4B). In this protein, a partial JMR may affect the
global free binding energy, contributing favorably to the ΔΔG value in the mutant (Table C and
Table D in S1 File). The energy contribution of the non-ATP binding site residues increases
the global energy binding of all KIT targets, decreasing the ΔΔG value, in particular for the sen-
sitive mutants KITWT and KITS628N.
In Imatinib•KITS628N complex, two residues, I789 and R791, located in the C-loop, supply
the most significant positive decrement to the binding energy, while residue D810 contributes
to the ‘negative’ increment (Fig 6). The impact of these two opposite effects is compensated
completely. Moreover, we observed that during the MD simulations of this complex, the
methyl-piperazinyl moiety of Imatinib abolished its interaction with I789 and established a
bifurcated H-bonding with D810 (Fig 4C). As already discussed, such alternation of the H-
bond pattern either is induced by a flipping of the methyl-piperazinyl fragment inside the
Fig 6. Binding energy of the Imatinib•target complexes. Difference in the per residues contribution to the binding energy (ΔΔG) between
the native and mutated targets–(top) CSF-1RWT and CSF-1RD802V(blue), and (bottom) KITWT, KITV560G (orange), KITS628N (green) and
KITD816V (red). The labeled residues are characterized by ΔΔG values more than 1 or less than -1 kcal/mol.
doi:10.1371/journal.pone.0160165.g006
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ATP-binding site or promotes such flipping, suggesting the induced fit of imatinib by the
ATP-binding site adjustment.
Formation of the salt-bridges in Imatinib•target complexes. Since we observed that the
charged residues have the highest impact on the binding energy contributions in all studied
complexes, we suggested a possible alteration of the salt-bridges in the mutants, especially in
the vicinity of the Imatinib-binding site. The salt-bridges, a peculiar type of non-covalent inter-
action, combines two main components—hydrogen bond and electrostatic interaction—
between two ionized sites.
Comparing the salt-bridges formed in the binding site of CSF-1RWT and CSF-1RD802V, we
observe that the salt-bridges D778•••R801 and D796•••K616, established in the native protein,
were completely disrupted in the mutant (Fig 7). As was identified through the MM-PBSA
computing, the residues establishing salt-bridges in CSF-1R are important contributors to the
total free binding energy with Imatinib, especially K616 (Table A in S1 File). All these residues
are located at proximity of the Imatinib binding pockets, in particular, D778 is in the C-loop,
D796 and R801 in the A-loop, and K616 in the β3 turn. The perturbed orientation of the side
chains of R801 and D796 in CSF-1RD802V mutant, correlated to the changed atomic fluctua-
tions (RMSFs), promotes their participation in an alternative salt-bridges pattern, forming in
particular, the bifurcate salt-bridges D778•••H776 and D796•••H776 (Fig 7).
In the native KIT, the salt-bridge D792•••R815 is equivalent to that found in CSF-1RWT. In
addition, D810 is bound to R791 (R791•••D810), completing a pattern of strong and paired
salt-bridge interactions stabilizing the KIT binding pocket, which is smaller than that in CSF-1R
(Fig 7). In KIT mutants, the salt-bridge pattern is considerably changed. In KITD816V mutant,
the most resistant to Imatinib, the salt-bridge D792•••R815 is absent. In KITV560G, sensitive to
Imatinib, residue D792 interacts either with R791 or with R815. In addition, in this mutant we
observed the salt-bridge interaction D810•••K623 found in CSF-1RWT. The Imatinib complex
formed by mutant KITS628N shows salt-bridges pattern similar to KITWT, nevertheless the inter-
actions stability is different, reflected in a lower occurrence when compared to the native target.
Such change of the salt-bridges pattern in the mutants compared to the native proteins is
prompted by an alternation of the atomic fluctuations (measured by the RMSFs) observed
principally in molecular fragments containing the residues involved in the salt-bridges forma-
tion. Our results suggest that in Imatinib•target complexes formed by the native receptors
(CSF-1RWT/KITWT) and by their mutants, sensitive (KITS628N) and very sensitive (KITV560G)
to Imatinib, the charges of residues localized at proximity of the binding pocket are equili-
brated through alternative salt-bridges which apparently contributes to the stabilization of the
binding pocket, providing the high affinity of Imatinib. In complexes formed by the resistant
mutants, CSF-1RD802V and KITD816V, the limited and locally positioned salt-bridges favor an
excess of positive charges on residues non-involved in salt-bridges at proximity of the binding
pocket (Fig D in S1 File) that would interfere with the Imatinib binding.
Conclusions
The gain-of-function mutations in RTKs alter not only their tight factor-depending regulation
but also influence their sensitivity to inhibitors, inducing drug resistance. In particular, it was
demonstrated that the V560G substitution in KIT promotes higher sensitivity to Imatinib,
while the substitution D816V in KIT and D802V in CSF-1R induces resistance to this drug
either systematically (in KIT), or occasionally (in CSF-1R).
Our in silico calculation performed on molecular dynamics trajectories demonstrate that
the native proteins and their mutants show different binding energy values with Imatinib, cor-
relating with the experimental data. The main factor that drives the targets responsiveness to
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Fig 7. Salt-bridges at proximity of the binding pocket calculated over the MD simulations of the Imatinib•target complexes.
Representative conformations of the proteins are shown as cartoon, Imatinib (in blue) and residues forming salt-bridges (in orange) are
drawn in stick. Non-covalent interactions are shown by dashed lines.
doi:10.1371/journal.pone.0160165.g007
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drug, sensitivity or resistance, is the electrostatic interactions between the protonated inhibitor
and the negatively charged residues in the ATP-binding site or in the proximity of this site.
The per residue energy decomposition indicates that the Asp to Val substitution in CSF-
1RD802V and KITD816V contributes the most to falling of the binding energy compared to the
other KIT mutants. The energy calculations of complexes formed with the KIT targets having
either the partially or entirely cleaved JMR showed that the JMR role in the Imatinib binding is
accessory. The salt-bridges pattern suggests that in the resistant mutants, CSF-1RD802V and
KITD816V, a charge redistribution within residues at the vicinity of the ATP-binding site favors
the repulsion of the positively charged Imatinib.
Supporting Information
S1 File. Scheme A. Structural formula of Imatinib. Atoms participating in the H-bonding
with the targets are shown. Fig A. Imatinib docking (best poses) into the targets, CSF-1R and
KIT. Structural formula of Imatinib is shown in the first box. Imatinib and protein residues that
interact directly with Imatinib are represented in sticks and the protein backbone is shown in
grey as cartoon. H-bonds between the protein and the ligand are shown as dotted lines. Fig B.
MD simulations of the KIT-Imatinib complexes. (A) The Root Mean Square Deviation
(RMSD) values of the complexes formed by Imatinib and KITWT (top) and its mutant KITD816V
(bottom) were calculated for the backbone atoms from replicas 1 and 2 separately (black and
red) of MD simulations of the studied systems. (B) Root Mean Square Fluctuations (RMSFs)
computed on the backbone atoms from replicas 1 and 2 separately (black and red). Fig C. Bind-
ing energy of imatinib•KIT targets. Graphical representation of the free binding energy (ΔG)
of Imatinib•target complexes. The MM-PBSA calculations were performed for KITWT,
KITS628N and KITD816V containing the partial JMR, identic to that in the mutant KITV560G. The
total ΔG energy value is shown for each complex. The ΔG value for KITV560G is reproduced for
comparison. Fig D. Electrostatic potential (EP) surface of the Imatinib•target complexes. EP
surface for each complex was obtained on a representative equilibrated conformation before the
MD simulations. EP calculations on the Connolly solvent-accessible surfaces of the receptors
were performed with the APBS software. The color scale ranges from red (electronegative
potential) through white (neutral) to blue (electropositive potential). Table A. Imatinib bind-
ing to the targets. Occurrences of the H-bonds between Imatinib and the targets residues were
calculated for each of the twoMD replicas (1 and 2). Imatinib atoms participating in the interac-
tions with the targets are represented in scheme A in S1 File. The atom pairs for donor-acceptor
interactions are depicted in the Table. Table B. The free energy of binding in the Imatinib-
RTK complexes (RTK = KITWT and KITD816V) The free binding energy (ΔGbind) and contri-
butions of electrostatic (ΔGelect), van der Waals (ΔGvdw) and solvation (ΔG solv) energies were
calculated using MM-PBSA for each of the two MD replicas (1 and 2). All energies are in kcal/
mol. Table C. Per residue contribution to the final binding energy in Imatinib•CSF-1R com-
plexes. Contribution of all residues from the ATP binding pockets and the point mutation (dis-
tinguished by yellow and orange background, respectively), and all residues contributing with
ΔΔG> 4 kcal/mol were considered. The favorable and unfavorable contributions of residues are
highlighted in green and red colour, respectively. Std is standard deviation. Table D. Per residue
contribution to the final binding energy in Imatinib•KIT complexes. Contribution of all resi-
dues from the ATP binding pockets and the point mutation (distigushed by yellow and by
orange background, respectively) and all charged residues contributing with ΔΔG> 4 kcal/mol
were considered. The favorable and unfavorable contributions of residues are highlighted in
green and red colour, respectively. Std is standard deviation.
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